• Health policy on November 6, and on November 7, too

    For the next nine days, Americans will finish the dogfight of the 2012 election. In health policy, this dogfight is, and ought to be, focused on the huge moral and ideological differences between the two coalitions represented by President Obama and Governor Romney.

    Democrats support the principle of (near-) universal coverage. The central claim on this side of the aisle is that every American, in every state, deserves access to affordable health insurance, and that substantial federal dollars and regulatory authority should be devoted to subsidizing low- and moderate-income citizens and those with high current or predicted health costs to acquire such coverage. In sheer dollar terms, the Affordable Care Act is the most progressive measure since the great society. It transfers roughly $200 billion annually down the income scale to provide health coverage and care. ACA also institutes a variety of measures, which I won’t discuss in detail here, to help finance expanded coverage. Within other domains of social insurance, Democrats support the continuation of a defined-benefit structure for Medicare, and a similar defined benefit structure supporting both state governments and individuals within the arena of Medicaid, with the federal government bearing the lion’s share of the burdens and risks associated with rising health costs.

    Republicans pledge to repeal and replace ACA. With varying degrees of explicitness, they reject ACA’s expansion of the social insurance compact, which Paul Ryan has called a “new entitlement we didn’t even ask for.” In ACA’s place, Republicans propose a more modest, decentralized alternative whose central specified features are HIPAA-like protections for the continuously-insured. To simplify a complex subject–and to fill in some fine print Republicans haven’t cared to specify in the campaign debate–they support shifting Medicare over time from a defined-benefit to a premium support, defined-contribution structure. Here insurer competition and the exercise of market choices by individual recipients are given central roles to control costs. Republicans support more radical transformation of Medicaid. Republican budgets and the Republican platform would block-grant and markedly cut federal contributions to Medicaid, providing states with greater operational flexibility, but shifting significant costs and risks onto lower levels of government and individual recipients.

    These are genuinely vast differences. Democrats would spend more money to guarantee near-universal coverage. Republicans would spend less, but would leave tens of millions more people uninsured. TIE readers must decide for themselves before next Tuesday which of these two visions of American social provision and health policy they wish to embrace.

    But what about November 7? What shall we do then? However the election is decided, I hope that policy experts and advocates on both sides find a way to more constructively cooperate when the campaign is done. I should add that I’m a pretty partisan figure myself. Yet one thing we’ve learned over time within our polarized and often-dysfunctional political system: Health policy is too large, too complex, too frightening, and too costly for one party to impose its vision or to carry the political load.

    In at least a few areas, I see some real possibilities for bipartisan compromise. These will be the subject of my next post. For the moment, though, I want to hold my cards close to the vest. I want to hear your ideas for policy areas and proposals that might attract real bipartisan support? Fire away.

     
    item.php
  • Kids are just the best

    This is a purely personal post, so if you only come here for the health policy, stop reading now.

    When you have kids, you want the best for them. As they grow and develop, you hope they turn out great. Deep down inside, you want them to be more capable than you. But every once in a while, it turns out they do something you didn’t even consider possible.

    For all my father’s efforts to make an athlete out of me, I was a super-nerd. I was the shortest kid in my class through high school. In middle school, I wrestled in an “optional” weight class that was so low, many schools didn’t field someone in it. But I was persistent, and I held my own. And, to my father’s credit, it was good for me. I take a certain amount of pride in the fact that I can play lots of sports, and I don’t worry about being able to throw any balls around with my kids or know what’s going on.

    But I live in the real world. In no way would I consider myself an “athlete”. So when I had kids, I assumed they’d be cut from the same cloth. Turns out that’s not the way it works.

    Our middle child (Noah) is a giant; I don’t know where he comes from. He’s consistently one of the tallest kids in his class. He has half an inch and 7 pounds on his older brother. And the kid can play. First, he was a star on his basketball team. Last year, he demanded to play football.

    Football was one of those sports my mother forbid when I was little. But all of Noah’s friends were playing, so we said yes. This year, though, when almost all his friends quit, Noah still wanted to do it. So every Saturday, he and I trudged out of the house at 7AM so he could warm up with his team before the 8AM game. That’s on top of the multiple practices a week he was already attending.

    I’m not a sports guy. I like to go to games, and I will watch if forced, but I don’t really follow teams, and I have to fake interest all the time. A couple weeks ago, it had poured all night, and at 7AM it was shockingly cold. Jacob had just woken up and didn’t want to go. My daughter was still asleep. So my wife (a much bigger fan than I) bailed and told me to take Noah without everyone else. This was the first game the rest of them missed.

    It was miserable. But all of a sudden, in the third quarter, the other team threw a pass. That doesn’t happen often in the third grade league. Completions are even rarer. So when the pass went up, we all were a little surprised. But no one was more surprised than I when Noah intercepted it.

    The place went crazy. Noah started running back up field, and he made it 50 yards before they brought him down. His team was all over him. His coaches were losing their minds. And I found myself standing in water, screaming so loud my throat hurt. Noah was so proud I thought he’d burst.

    My wife still hasn’t forgiven herself for missing it.

    It’s so strange to watch my child excel at something I can’t even comprehend. I have no frame of reference. I don’t even understand half of what he’s telling me about what he’s doing.

    More importantly, it’s forced me to realize that he’s his own person. He’s going to do things I can’t imagine. The same goes for Jacob and Sydney, both of whom exhibit traits that I don’t have.

    I took the picture on the right (which alone justified the cost of the DLR camera) and blew it up to poster size for Noah to put on his wall. The truth of the matter is that I want it on my wall too. I know it’s “just” third-grade football. I don’t care. To see my name, worn by a kid who looks like me, doing something I never thought possible is absolutely, positively one of the most incredible feelings I can describe.

    Being a parent is amazing, and never for the reasons you expect.

    @aaronecarroll

     
    item.php
  • Sex voucher

    From the New Yorker:

    @afrakt

     
    item.php
  • Reading list

    Cost Effectiveness Analysis and the Design of Cost-Sharing in Insurance: Solving a Puzzle, by Mark Pauly  (The National Bureau of Economic Research)

    The conventional model for the use of cost effectiveness analysis for health programs involves determining whether the cost per unit of effectiveness of the program is better than some socially determined maximum acceptable cost per unit of effectiveness. If a program is better, the policy implication is that it should be implemented by full coverage of its cost by insurance; if not, no coverage should be provided and the program should not be implemented. This paper examines the unanswered question of how cost effectiveness analysis should be performed and interpreted when insurance coverage can involve non-negligible cost sharing. It explores both the question of how cost effectiveness is affected by the presence of cost sharing, and the more fundamental question of cost effectiveness when cost sharing is itself set at the cost effective level. Both a benchmark model where only “societal” preferences (embodied in a threshold value of dollars per unit of health) matter and a model where individual willingness to pay can be combined with societal values are considered. A common view that cost sharing should vary inversely with program cost effectiveness is shown to be incorrect. A key issue in correct analysis is whether there is heterogeneity either in marginal effectiveness of care or marginal values of care that cannot be perceived by the social planner but is known by the demander. The cost effectiveness of a program is shown to depend upon the level of cost sharing; it is possible that some programs that would fail the social test at both zero coverage and full coverage will be acceptable with positive cost sharing. Combining individual and social preferences affects both the choice of programs and the extent of cost sharing.

    Behavioral Hazard in Health Insurance, by Katherine Baicker, Sendhil Mullainathan and Joshua Schwartzstein (The National Bureau of Economic Research)

    This paper develops a model of health insurance that incorporates behavioral biases. In the traditional model, people who are insured overuse low value medical care because of moral hazard. There is ample evidence, though, of a different inefficiency: people underuse high value medical care because they make mistakes. Such “behavioral hazard” changes the fundamental tradeoff between insurance and incentives. With only moral hazard, raising copays increases the efficiency of demand by ameliorating overuse. With the addition of behavioral hazard, raising copays may reduce efficiency by exaggerating underuse. This means that estimating the demand response is no longer enough for setting optimal copays; the health response needs to be considered as well. This provides a theoretical foundation for value-based insurance design: for some high value treatments, for example, copays should be zero (or even negative). Empirically, this reinterpretation of demand proves important, since high value care is often as elastic as low value care. For example, calibration using data from a field experiment suggests that omitting behavioral hazard leads to welfare estimates that can be both wrong in sign and off by an order of magnitude. Optimally designed insurance can thus increase health care efficiency as well as provide financial protection, suggesting the potential for market failure when private insurers are not fully incentivized to counteract behavioral biases.

    Why Doctors Prescribe Opioids to Known Opioid Abusers, by Anna Lembke (The New England Journal of Medicine)

    @afrakt

     
    item.php
  • Cause and Affect – ctd.

    I’ve written previously about how I feel like residency can often dampen empathy. But that’s after graduation. Medical school is no picnic either. I remember that we used to joke that if someone didn’t make you cry on your surgery rotation, then you must be doing something wrong.

    As I get older, that seems less and less funny. Then I saw this. “Medical students still suffer mistreatment by faculty, resident doctors, and nurses, US report says“:

    More than half of medical students reported some mistreatment during their third year, when they began clinical clerkships and to work with residents, attending physicians, medical school faculty, nurses, and patients, and family members, found the study, published in Academic Medicine, the journal of the Association of American Medical Colleges.

    Categories of mistreatment included physical, verbal, and sexual harassment and ethnic and power abuse problems, which were categorized as mild, moderate, and severe.

    This piece reports on efforts at the David Geffen School of Medicine of the University of California, Los Angeles to curb mistreatment:
    The study reviewed medical students’ reports of mistreatment during four periods: 1996-8 (before the implementation of interventions); 1999-2000 (the two years immediately after reporting initiatives were introduced); 2001-5 (during which the school’s gender and power abuse committee established a formal reporting and investigation system); and 2006-8 (the period after the California legislature required all state employed supervisors, including university faculty and staff, to complete a two hour online sexual harassment training course every two years and during which the medical school introduced a session on mistreatment for students).
    The surveys had a response rate of more than 90%, which is just insanely high. Here’s the depressing bit: More than half of medical students reported mistreatment. Most of it was verbal or power related, but 5% was physical. That’s horrifying. Women were more likely to be mistreated than men. Few students reported it or looked for assistance.

    The levels and types of mistreatment didn’t change in any of the study periods. In other words, the efforts to make things better didn’t seem to work.

    According to the story, when the doctors were notified of these results, they were shocked. I don’t know why. I remember medical school. I saw some terrible behavior then, and I still hear about some now.

    People wonder why doctors can sometimes seem uncaring or disconnected. They sometimes blame it on the constant exposure to pain or suffering. But I think we, as a profession, are somewhat to blame for fostering an atmosphere we would find repugnant in any other setting. I’ve written about it before. Perhaps it’s time we remember that our trainees are people too, and just as worthy of respect and empathy as patients.

    @aaronecarroll

     

     
    item.php
  • Killing Osama Bin Laden and sleep science (recently read books)

    No Easy Day: The Firsthand Account of the Mission That Killed Osama Bin Laden, by Mark Owen and Kevin Maurer: It beats me why this ended up on my book reading list. Probably I heard something about it that made it sound good. Not to take anything away from the dedicated, military professionals that serve our country in ways I never have or could, it really wasn’t. It wasn’t a total bust either. Only Chapter 9 to the end was directly about killing Osama Bin Laden, and I found some enjoyment in reading the tale. But the filler up to Chapter 9 did little for me. Your mileage may vary.

    Dreamland: Adventures in the Strange Science of Sleep, by David Randall: I probably didn’t need to read this one since I’m pretty well versed in the science of sleep. If you’re not, though, I recommend it. I was pleased to see some pages devoted to cognitive behavioral therapy for insomnia. I enjoyed learning about the intersection of professional (and Olympic) athletics and sleep science. A taste:

    The Stanford researchers dug through twenty-five years of Monday night NFL games and flagged every time a West Coast team played an East Coast team. Then, in an inspired move, they compared the final scores for each game with the point spread developed by bookmakers in Vegas. The results were stunning. The West Coast teams dominated their East Coast opponents no matter where they played. A West Coast team won by 63 percent of the time, by an average of two touchdowns.

    You’ll have to read the book to learn how sleep explains why West beats East, on average.

    @afrakt

     
    item.php
  • NPR program on compounding pharmacies

    I’ll be on NPR’s Talk of the Nation today from 3.15 – 4 pm ET, discussing the regulation of compounding pharmacies. Prior TIE coverage here.

    UPDATE:  audio here.

    @koutterson

     

     
    item.php
  • Communication is poor when it comes to chemo, but who is to blame?

    New study published in the NEJM. “Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer“:

    BACKGROUND: Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative.

    METHODS: We studied 1193 patients participating in the Cancer Care Outcomes Research and Surveillance (CanCORS) study (a national, prospective, observational cohort study) who were alive 4 months after diagnosis and received chemotherapy for newly diagnosed metastatic (stage IV) lung or colorectal cancer. We sought to characterize the prevalence of the expectation that chemotherapy might be curative and to identify the clinical, sociodemographic, and health-system factors associated with this expectation. Data were obtained from a patient survey by professional interviewers in addition to a comprehensive review of medical records.

    This feels like the flip side of yesterday’s post, where big effects were often found to be outliers. In this study, patients were asked about their expectations for chemotherapy for metastatic lung or colorectal cancer. The bad news is that these cancers have terrible prognoses. Chemotherapy is still the treatment of choice, but the effect we’re hoping for is an extension of life by weeks to months. Maybe you’ll see some relief of symptoms. But it’s not going to be curative. There are also, of course, significant side effects.

    Therefore, there is no “right” answer with respect to whether to engage in therapy. Some choose to use the chemo, some don’t. But what we really want is for those decisions to be informed.

    That’s what this study was trying to measure. They asked almost 1200 patients with incurable cancer what their expectations with chemotherapy were. The results weren’t good. Almost 70% of those with lung cancer and more than 80% of those with colorectal cancer did not understand that chemotherapy wasn’t going to cure their cancer. What was surprising to me was that people who reported that they had good communication were more likely to believe incorrectly that chemotherapy might cure them. Being more educated did not improve understanding, nor did an improved functional status or the patient’s role in decision making.

    It’s hard to know where the lesion is here. Is it with patients, who aren’t listening well? Is it with physicians, who aren’t able to convey the bad news? We can’t tell. I’m a bit concerned that the reasons misinformed patients were more likely to report favorably about communication with their physicians is that patients who heard good news from their doctors liked their doctors more. That bodes poorly for the ability of both sides to make this better.

    @aaronecarroll

     
    item.php
  • Wussinomics

    Hey, homo economicus, you looking for a good time? Then try a little bit of Mark Pauly’s Wussinomics: the state of competitive efficiency in private health insurance. I’m not kidding, this is a fun read. Some quotes:

    • “I believe that, in theory, a competitive insurance market should lead to efficient levels of care and efficient rates of growth in medical spending for the great majority of Americans, who are not poor and not stupid.”
    • “The contentious data on the rates of growth of private versus Medicare premiums shows at best equivalent growth for private premiums; private insurers have not been more successful than government in cost-containment.”
    • “[C]ut the price, see what happens to quantity, and if it does not fall enough (or even does not fall), cut the price further.”
    • “As an antidote to this kind of story of timidity in the face of the obvious, private insurers are always happy to recount their latest creative steps in redesigning insurance for cost containment. […] Without being a total wet blanket, as an honest observer I can say that more of these initiatives have failed than succeeded.”
    • “What is even more troubling is that this history has not sunk in; instead new ideas (or retreads of old ideas) are offered as ‘evidence’ that a political goal of improving quality by controlling cost is within our grasp. Of course, the world needs cheerleaders, and it is hardly surprising that advocates pass by downsides and risks. But, since a new crop of politicians desperately wanting to avoid painful tradeoffs appears every few years, the attraction of magical thinking and doing the impossible continues not just to resonate but to distract policymakers from the hard choices.”
    • “I think the failure so far to focus on cost reducing but slightly quality reducing innovation is a large share of the problem—at least as it applies to new technology.”
    • “[A]part from varying the size of networks, plans have never systematically varied other dimensions of care, like the amount and form of new technology, and competed vigorously on that basis. Instead they waste their time trying to get people to exercise and eat less.”
    • “Guaranteed renewability, group to individual conversion, and some decent high risk pools are all we need, plus the hope that exchanges if they happen will not make things worse.”
    • “Given the general unpopularity and logical disconnect associated with measures that save on cost but irritate consumers, it may be no surprise that private insurers want Medicare to break trail—thus providing them a safe path as they follow along.”
    • “I believe it is not outside the realm of human ingenuity to design a program with political and legal safe harbors, and (if things get bad enough) even get such a program into law. It will require a lot; politicians will have to say that it is all right for your insurer to mistreat you if that is what goes along with the low cost plan you voluntarily chose.”
    • “We moderately well-off are still numerous enough that our preference drove the style of care, but the resulting cost increases, more or less uniform across the board, that took an affordable bite out of our income growth cut much more for lower income people and even caused some of them to drop out of the insurance system entirely and put their children on Medicaid or SCHIP. […] A fundamental solution, which I would favor if I knew how to bring it about, would be to alter the pattern of income growth going forward toward one with a more equal distribution of gains.”

    For his forthrightness, I tip my hat to Pauly. Too few who favor more market solutions will admit that, to date, the private sector has disappointed as much or more than government. Too few of them will say that one of the reasons is that the private sector looks to government (Medicare) for CYA. Too few build into their reform proposals safe harbor for insurers to deny claims based on sanctioned evidence (in some way to be defined). And, clearly, it is not universally believed that we need a more equal distribution of the growth in incomes. Apart from the last point, do any political leaders say any of these things? If they do, it is both rare and obfuscated. Do you think Pauly speaks the truth here? Can you (we) handle the truth?

    @afrakt

     
    item.php
  • Research is usually comprised of baby steps

    Yeah, there’s an election going on. I’m still going to bring you research. I saw another great study yesterday that you should know about. “Empirical Evaluation of Very Large Treatment Effects of Medical Interventions“:

    Context  Most medical interventions have modest effects, but occasionally some clinical trials may find very large effects for benefits or harms.

    Objective  To evaluate the frequency and features of very large effects in medicine.

    Data Sources  Cochrane Database of Systematic Reviews (CDSR, 2010, issue 7).

    Study Selection  We separated all binary-outcome CDSR forest plots with comparisons of interventions according to whether the first published trial, a subsequent trial (not the first), or no trial had a nominally statistically significant (P < .05) very large effect (odds ratio [OR], ≥5). We also sampled randomly 250 topics from each group for further in-depth evaluation.

    Data Extraction  We assessed the types of treatments and outcomes in trials with very large effects, examined how often large-effect trials were followed up by other trials on the same topic, and how these effects compared against the effects of the respective meta-analyses.

    I’ve complained many times that research is glacial work. Almost always, you’re trying to take baby steps. It also is expensive. So it can be frustrating, especially when the general public thinks every study should cure cancer. The problem is compounded each time some news story breaks about the “unbelievable leap forward” some lab or group has just made. So why don’t those announcements and press releases seem to bear fruit?

    The study above examined “blockbuster” results in over 3000 reviews. What they did is to look for trials with huge results. They also looked to see whether those trials were the first in the area, or were repeated studies of prior findings. They also looked at whether those findings held up after further testing.

    Let’s start here: Of the analyses they conducted, 9.7% had a large effect seen in the first published trial, 6.1% had a study with a large effect in a trial that didn’t come first, and 84.2% had no trials with large effects. Right off the bat, I hope you see that the vast majority of studies don’t show large effects.

    First trials with large effects were small. They had a median of 18 events in them. Not that subsequent large effect trials were bigger; they had a median of 15 events.

    Trials with large effects were significantly less likely to address mortality, and significantly more likely to focus on efficacy in the laboratory.

    Here’s the kicker, though. Almost 90% of first trials that showed large effects saw them fade in later trials. Almost 98% of subsequent trials with large effects saw that happen. Large effects rarely hold. And lest you think that large effect trials were just more likely to be checked up on, trials with large and non-large effects were just as likely to have subsequent published trials.

    It’s not all bad news. There were some results that held. Just over 9% of trials with a large effect maintained those results in meta-analysis. None of these, however, were studies that looked at mortality-related outcomes.

    In the entire Cochrane Database of Systematic Reviews (more than 3000 studied), only one intervention had a large effect on mortality that held up under further scrutiny. Extracorporeal oxygenation (ECMO) for newborns reduced mortality in infants with severe respiratory failure. You’re going to trust me that this isn’t the kind of thing you’d ever want to be commonly used.

    Although the media like to trumpet big, huge findings with promises of huge changes in real outcomes, those kind of results just don’t happen often at all in real research. Those results almost always fade in subsequent work. When they do hold up, they are usually not in big-impact areas like preventing death or curing disease.

    You should be skeptical of such things, not just because your gut tells you so. You should be skeptical because of findings like these.

    @aaronecarroll

     
    item.php